ArticleMaterials today. Bio2026
Enhanced ocular delivery of tacrolimus via cationic nanoliposomes: Mitigating inflammation and rebalancing Th17/Treg responses in dry eye disease.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a common ocular surface disorder characterized by persistent inflammation and immune imbalance, leading to visual impairment and substantial deterioration in quality of life. Although topical medications remain the mainstay of DED management, their therapeutic effectiveness is frequently limited by poor corneal penetration, low ocular bioavailability, and potential safety issues associated with long-term administration. To address this, we engineered a low-dose cationic tacrolimus nanoliposome delivery system (FK506 NLPs) designed to enhance ocular surface drug availability while targeting immune-inflammatory dysregulation. The positively charged NLPs exhibited prolonged corneal residence via mucoadhesion and improved drug permeation. In a murine model of DED, FK506 NLPs accelerated ocular surface repair, improved tear film stability, and preserved conjunctival goblet cells and lacrimal gland structure. Mechanistically, they suppressed the expression of key proinflammatory mediators in both corneal and lacrimal tissues and restored immune homeostasis by re-establishing the balance between Th17 and regulatory T cells. Importantly, FK506 NLPs also exhibited favorable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.